---
document_datetime: 2025-06-11 09:27:57
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/zostavax-epar-all-authorised-presentations_en.pdf
document_name: zostavax-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.8749747
conversion_datetime: 2025-12-24 01:33:05.418393
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) Number            | (Invented) name   | Strength   | Pharmaceutical form                                                                     | Route of administration                    | Immediate Packaging                                                  | Content (concentration)   | Pack size                                                |
|---------------------------|-------------------|------------|-----------------------------------------------------------------------------------------|--------------------------------------------|----------------------------------------------------------------------|---------------------------|----------------------------------------------------------|
| EU/1/06/341/001           | Zostavax          | --1        | Powder and solvent for suspension for injection                                         | Intramuscular use, Subcutaneous use        | powder: vial (glass); solvent: vial (glass)                          | 0.65 mL                   | 1 vial + 1 vial                                          |
| EU/1/06/341/002           | Zostavax          | --1        | Powder and solvent for suspension for                                                   | Intramuscular use, Subcutaneous use        | powder: vial (glass); solvent: vial (glass)                          | 0.65 mL                   | 10 vials + 10 vials                                      |
| EU/1/06/341/005           | Zostavax          | --1        | injection Powder and solvent for suspension for injection in a pre-                     | Intramuscular use, Subcutaneous use        | powder: vial (glass); solvent: pre-filled syringe (glass) authorised | 0.65 mL                   | 1 vial + 1 pre-filled syringe without needle             |
| EU/1/06/341/006           | Zostavax          | --1        | filled syringe Powder and solvent for suspension for injection in a pre- filled syringe | Intramuscular use, Subcutaneous use longer | powder: vial (glass); solvent: pre-filled syringe (glass)            | 0.65 mL                   | 10 vials + 10 pre- filled syringes without needle        |
| EU/1/06/341/007           | Zostavax          | --1        | Powder and solvent for suspension for injection in a pre- filled syringe no             | Intramuscular use, Subcutaneous use        | powder: vial (glass); solvent: pre-filled syringe (glass)            | 0.65 mL                   | 20 vials + 20 pre- filled syringes without needle        |
| EU/1/06/341/008           | Zostavax          | --1        | Powder and solvent for suspension for injection in a pre- filled syringe product        | Intramuscular use, Subcutaneous use        | powder: vial (glass); solvent: pre-filled syringe (glass)            | 0.65 mL                   | 1 vial + 1 pre-filled syringe + 1 separate needle        |
| EU/1/06/341/009           | Zostavax          | --1        | Powder and solvent for suspension for injection in a pre- filled syringe                | Intramuscular use, Subcutaneous use        | powder: vial (glass); solvent: pre-filled syringe (glass)            | 0.65 mL                   | 10 vials + 10 pre- filled syringes + 10 separate needles |
| EU/1/06/341/010 Medicinal | Zostavax          | --1        | Powder and solvent for suspension for injection in a pre- filled syringe                | Intramuscular use, Subcutaneous use        | powder: vial (glass); solvent: pre-filled syringe (glass)            | 0.65 mL                   | 20 vials + 20 pre- filled syringes + 20 separate needles |

<div style=\"page-break-after: always\"></div>

| MA (EU) Number   | (Invented) name   | Strength   | Pharmaceutical form                                                      | Route of administration             | Immediate Packaging                                                  | Content (concentration)   | Pack size                                                |
|------------------|-------------------|------------|--------------------------------------------------------------------------|-------------------------------------|----------------------------------------------------------------------|---------------------------|----------------------------------------------------------|
| EU/1/06/341/011  | Zostavax          | --1        | Powder and solvent for suspension for injection in a pre- filled syringe | Intramuscular use, Subcutaneous use | powder: vial (glass); solvent: pre-filled syringe (glass)            | 0.65 mL                   | 1 vial + 1 pre-filled syringe + 2 separate needles       |
| EU/1/06/341/012  | Zostavax          | --1        | Powder and solvent for suspension for injection in a pre- filled syringe | Intramuscular use, Subcutaneous use | powder: vial (glass); solvent: pre-filled syringe (glass) authorised | 0.65 mL                   | 10 vials + 10 pre- filled syringes + 20 separate needles |
| EU/1/06/341/013  | Zostavax          | --1        | Powder and solvent for suspension for injection in a pre- filled syringe | Intramuscular use, Subcutaneous use | powder: vial (glass); solvent: pre-filled syringe (glass)            | 0.65 mL                   | 20 vials + 20 pre- filled syringes + 40 separate needles |

--1 After reconstitution, one dose (0.65 mL) contains: Varicella-zoster virus 1 , Oka/Merck strain, (live, attenuated) not less than 19,400 PFU 2 1 produced in human diploid (MRC-5) cells 2  PFU = Plaque-forming units Medicinal product no longer authorised